Listed

Pediatrix Medical Group, Inc.

MDNYSECIK 893949HealthcareFiscal year ends Dec 31

Latest reported revenue, Q3 FY2026$501.4mRevenue, Q3 FY2026, three months to 2026-09-30$501.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Report this figureThree months to Sep 30, 2026, from the 10-Q filed Oct 29, 2026.

Latest quarter: Q3 FY2026

Three months to Sep 30, 2026, against the same quarter a year earlier.

  • Revenue$501.4mRevenue, Q3 FY2026, three months to 2026-09-30$501.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Report this figure+1.7% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin13.0%Operating margin, Q3 FY2026, three months to 2026-09-30. operating income / revenueOperating income: $65.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Revenue: $501.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Report this figure−0.8 pts on a year earlier
  • Net margin9.4%Net margin, Q3 FY2026, three months to 2026-09-30. net income / revenueNet income: $47.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Revenue: $501.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Report this figure−5.2 pts on a year earlier
  • Diluted EPS$0.59Diluted EPS, Q3 FY2026, three months to 2026-09-30$0.59 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Report this figure−29.8% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$501.4mOperating margin 13.0%
Diluted EPS$0.59, Q3 FY2026
Pediatrix Medical Group, Inc., key figures for the last eight quarters
Line itemUnitQ4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30Shape over the periods
Revenue$m502Revenue, Q4 FY2024, three months to 2024-12-31$502.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074. Derived: 12-month figure less the 9-month figure.Report this figure458Revenue, Q1 FY2025, three months to 2025-03-31$458.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-05, accession 0001193125-26-204993.Report this figure469Revenue, Q2 FY2025, three months to 2025-06-30$468.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-04, accession 0001193125-26-331513.Report this figure493Revenue, Q3 FY2025, three months to 2025-09-30$492.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Report this figure494Revenue, Q4 FY2025, three months to 2025-12-31$493.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074. Derived: 12-month figure less the 9-month figure.Report this figure476Revenue, Q1 FY2026, three months to 2026-03-31$476.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-05, accession 0001193125-26-204993.Report this figure488Revenue, Q2 FY2026, three months to 2026-06-30$487.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-04, accession 0001193125-26-331513.Report this figure501Revenue, Q3 FY2026, three months to 2026-09-30$501.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%7.8%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $39.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0001193125-26-058074. Derived: 12-month figure less the 9-month figure.Revenue: $502.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074. Derived: 12-month figure less the 9-month figure.Report this figure7.0%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $32.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001193125-26-204993.Revenue: $458.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-05, accession 0001193125-26-204993.Report this figure12.8%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $59.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001193125-26-331513.Revenue: $468.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-04, accession 0001193125-26-331513.Report this figure13.8%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $68.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Revenue: $492.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Report this figure9.9%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $48.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0001193125-26-058074. Derived: 12-month figure less the 9-month figure.Revenue: $493.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074. Derived: 12-month figure less the 9-month figure.Report this figure8.7%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $41.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001193125-26-204993.Revenue: $476.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-05, accession 0001193125-26-204993.Report this figure11.7%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $56.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001193125-26-331513.Revenue: $487.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-04, accession 0001193125-26-331513.Report this figure13.0%Operating margin, Q3 FY2026, three months to 2026-09-30. operating income / revenueOperating income: $65.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Revenue: $501.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Report this figure
Net margin%6.1%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $30.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0001193125-26-058074. Derived: 12-month figure less the 9-month figure.Revenue: $502.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074. Derived: 12-month figure less the 9-month figure.Report this figure4.5%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $20.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Revenue: $458.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-05, accession 0001193125-26-204993.Report this figure8.4%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $39.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Revenue: $468.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-04, accession 0001193125-26-331513.Report this figure14.5%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $71.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Revenue: $492.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Report this figure6.8%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $33.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0001193125-26-058074. Derived: 12-month figure less the 9-month figure.Revenue: $493.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074. Derived: 12-month figure less the 9-month figure.Report this figure6.2%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $29.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Revenue: $476.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-05-05, accession 0001193125-26-204993.Report this figure8.2%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $39.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Revenue: $487.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-08-04, accession 0001193125-26-331513.Report this figure9.4%Net margin, Q3 FY2026, three months to 2026-09-30. net income / revenueNet income: $47.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Revenue: $501.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Report this figure
Diluted EPS$ per sharenot reported (Diluted EPS not reported)0.24Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001193125-26-204993.Report this figure0.46Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001193125-26-331513.Report this figure0.84Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Report this figurenot reported (Diluted EPS not reported)0.36Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001193125-26-204993.Report this figure0.49Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001193125-26-331513.Report this figure0.59Diluted EPS, Q3 FY2026, three months to 2026-09-30$0.59 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001193125-26-436952.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$1.91bnOperating margin 10.9%
Diluted EPS$1.94, FY2025
Pediatrix Medical Group, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m1,911Revenue, FY2021, twelve months to 2021-12-31$1.91bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-02-20, accession 0000950170-24-016794.Report this figure1,972Revenue, FY2022, twelve months to 2022-12-31$1.97bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-02-20, accession 0000950170-25-023730.Report this figure1,995Revenue, FY2023, twelve months to 2023-12-31$1.99bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074.Report this figure2,013Revenue, FY2024, twelve months to 2024-12-31$2.01bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074.Report this figure1,914Revenue, FY2025, twelve months to 2025-12-31$1.91bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%10.6%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $202.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-20, accession 0000950170-24-016794.Revenue: $1.91bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-02-20, accession 0000950170-24-016794.Report this figure8.8%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $172.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-20, accession 0000950170-25-023730.Revenue: $1.97bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-02-20, accession 0000950170-25-023730.Report this figure0.4%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $7.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0001193125-26-058074.Revenue: $1.99bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074.Report this figure(3.4%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$68.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0001193125-26-058074.Revenue: $2.01bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074.Report this figure10.9%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $208.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0001193125-26-058074.Revenue: $1.91bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074.Report this figure
Net margin%6.9%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $131.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-20, accession 0000950170-24-016794.Revenue: $1.91bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2024-02-20, accession 0000950170-24-016794.Report this figure3.4%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $66.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-20, accession 0000950170-25-023730.Revenue: $1.97bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-02-20, accession 0000950170-25-023730.Report this figure(3.0%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$60.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0001193125-26-058074.Revenue: $1.99bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074.Report this figure(4.9%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$99.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0001193125-26-058074.Revenue: $2.01bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074.Report this figure8.6%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $165.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0001193125-26-058074.Revenue: $1.91bn. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-02-19, accession 0001193125-26-058074.Report this figure
Diluted EPS$ per share1.53Diluted EPS, FY2021, twelve months to 2021-12-31$1.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-20, accession 0000950170-24-016794.Report this figure0.79Diluted EPS, FY2022, twelve months to 2022-12-31$0.79 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-20, accession 0000950170-25-023730.Report this figure(0.73)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.73 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-19, accession 0001193125-26-058074.Report this figure(1.19)Diluted EPS, FY2024, twelve months to 2024-12-31−$1.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-19, accession 0001193125-26-058074.Report this figure1.94Diluted EPS, FY2025, twelve months to 2025-12-31$1.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-19, accession 0001193125-26-058074.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Pediatrix Medical Group, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$347.4m13,714,275Added+139,902
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$151.6m5,985,147Reduced−168,979
DIMENSIONAL FUND ADVISORS LP2026-06-30$106.9m4,220,311Added+363,396
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$91.7m3,620,040Reduced−36,281
STATE STREET CORP2026-06-30$89.5m3,533,248Added+154,748
VICTORY CAPITAL MANAGEMENT INC2026-06-30$86.6m3,416,913Reduced−425,020
WASATCH ADVISORS LP2026-06-30$63.3m2,498,884Added+448,360
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$56.4m2,226,028Added+38,061
AMERICAN CENTURY COMPANIES INC2026-06-30$55.5m2,192,017Reduced−1,733,349
FULLER & THALER ASSET MANAGEMENT, INC.2026-06-30$43.6m1,721,451Added+492,020

Recent filings

All 1,033 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Pediatrix Medical Group, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2907:00 ET10-QQuarterly reportPeriod 2026-09-300001193125-26-436952
2026-10-2906:50 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-436932
2026-08-0407:00 ET10-QQuarterly reportPeriod 2026-06-300001193125-26-331513
2026-08-0406:50 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-331488
2026-07-2417:00 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure0001193125-26-316225
2026-07-1507:00 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-304033
2026-05-0716:30 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001193125-26-212117
2026-05-0507:00 ET10-QQuarterly reportPeriod 2026-03-310001193125-26-204993
2026-05-0506:50 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-204982
2026-03-2706:50 ETDEF 14AProxy statementPeriod 2026-03-250001193125-26-127299

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 19, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures.See the target

About the filer

CIK
893949
Tickers
MD
Exchange
NYSE
SIC code
8060 Services-Hospitals
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
FL
Filer category
Large accelerated filer
Former names
MEDNAX, INC. (to 2022-06-21); PEDIATRIX MEDICAL GROUP INC (to 2009-01-02)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 07:14 ET. Listed shows no prices and gives no investment advice.